325 related articles for article (PubMed ID: 17594363)
1. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
[No Abstract] [Full Text] [Related]
2. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
[TBL] [Abstract][Full Text] [Related]
4. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer drugs. Making sense of the options.
Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308
[No Abstract] [Full Text] [Related]
6. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
Kaprin AD; Gafanov PA; Fastovets SV
Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
[No Abstract] [Full Text] [Related]
7. Advanced prostate cancer. Hormonal treatment.
de la Haba-Rodríguez J
Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
[No Abstract] [Full Text] [Related]
8. Multiple intracrine hormonal targets in the prostate: opportunities and challenges.
Labrie F
BJU Int; 2007 Jul; 100 Suppl 2():48-51. PubMed ID: 17594360
[No Abstract] [Full Text] [Related]
9. Hormonal treatment of prostate cancer.
Garnick MB
N Engl J Med; 1999 Mar; 340(10):812-3. PubMed ID: 10075531
[No Abstract] [Full Text] [Related]
10. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
Koutsilieris M; Mitsiades C; Dimopoulos T; Vacalicos J; Lambou T; Tsintavis A; Milathianakis C; Bogdanos J; Karamanolakis D
Expert Opin Investig Drugs; 2002 Feb; 11(2):283-93. PubMed ID: 11829717
[TBL] [Abstract][Full Text] [Related]
11. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for prostate cancer: the role of hormonal treatment.
Shahani R; Fleshner NE; Zlotta AR
Discov Med; 2007 Aug; 7(39):118-24. PubMed ID: 18093474
[TBL] [Abstract][Full Text] [Related]
14. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-androgens: role in treating advanced prostate cancer.
Newton M; Kosier JH
Urol Nurs; 1998 Mar; 18(1):56-7, 83. PubMed ID: 9582897
[No Abstract] [Full Text] [Related]
16. Prostate cancer: the role of hormonal therapy.
Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and prostate cancer.
Dacker R
Radiol Technol; 1997; 68(3):194-5. PubMed ID: 9008013
[No Abstract] [Full Text] [Related]
18. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.
Schally AV
BJU Int; 2007 Jul; 100 Suppl 2():2-4. PubMed ID: 17594347
[No Abstract] [Full Text] [Related]
19. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
Lebret T; Méjean A
Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
[TBL] [Abstract][Full Text] [Related]
20. [New anti-androgen and luteinizing hormone releasing hormone antagonist for the treatment of advanced prostate cancer].
Furuya Y; Masai M
Nihon Rinsho; 2000 Jul; 58 Suppl():317-9. PubMed ID: 11022739
[No Abstract] [Full Text] [Related]
[Next] [New Search]
